Pfizer Inc. (NYSE:PFE) Shares Sold by Farmers National Bank

Farmers National Bank decreased its stake in Pfizer Inc. (NYSE:PFE) by 2.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 102,472 shares of the biopharmaceutical company’s stock after selling 2,536 shares during the period. Farmers National Bank’s holdings in Pfizer were worth $2,867,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Olistico Wealth LLC purchased a new position in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $29,000. Quarry LP purchased a new position in Pfizer during the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its stake in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on PFE shares. Barclays increased their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, September 16th. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

Pfizer stock opened at $28.67 on Wednesday. The company has a market cap of $162.46 billion, a P/E ratio of -477.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a one year low of $25.20 and a one year high of $34.11. The business has a fifty day moving average of $29.28 and a two-hundred day moving average of $28.31. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the business earned $0.67 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.